Abstract Lynch syndrome, a heritable form of cancer predisposition, is caused by germline mutations within genes of the DNA mismatch repair family, and can be rapidly identified in young onset cancer patients through the detection of loss of expression of at least one of these genes in tumour samples. To date, such causative mutations have only been identified within exonic and splice site regions. Though this approach has been successful in the majority of families, a considerable number remain in which no mutation has been found. To address this situation, we used an alternative mutation discovery procedure which involved haplotype analysis of the locus containing the gene lost in the tumour and delineation of segregating haplotypes, followed by an investigation of splicing aberrations to uncover cryptic splice sites which lay outside the genomic regions routinely examined for mutations. In this report, we show that an intronic mutation 478 bp upstream of exon 2 in the MSH2 gene causes Lynch syndrome through creation of a novel splice donor site with subsequent pseudoexon activation, thus highlighting the need for more extensive sequencing approaches in families where routine procedures fail to find a mutation.
Introduction
Colorectal cancer (CRC) is the 3rd most common form of cancer in the United States and has the third highest morbidity [1] . Heritable forms of this disease account for approximately 20% of cases and of these around 20% are either confirmed or suspected carriers of a mutation within one of the four primary DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6 or PMS2). Individuals are suspected of carrying a Lynch syndrome (MIM120435) associated mutation if they have a strong family history of colorectal cancer such that they meet either the Amsterdam [2] or the Bethesda criteria [3] . Lynch syndrome is an autosomal dominantly-inherited cancer predisposition with high penetrance, and therefore the identification of all relatives carrying the family mutation is of paramount importance in the prevention of colorectal and other spectrum cancers. In a suspected Lynch syndrome family, an individual's tumour is assessed for microsatellite instability (MSI) and immunohistochemical (IHC) absence of the mismatch repair proteins, both of which are hallmarks of the Lynch syndrome phenotype. To enable appropriate diagnosis, counselling and surveillance, the MMR gene indicated by the IHC MMR deficiency profile [4] , is screened for causative mutations by Sanger sequencing of exonic and flanking splice site regions and by MLPA (multiplex ligation-dependant PCR amplification) testing for large exonic deletions and duplications.
Using these selective sequencing approaches, causative mutations have been identified in the majority of CRC cases suspected of Lynch syndrome, however there remains a substantial proportion of families (where affected individuals demonstrate MMR IHC deficiency and/or MSI in the presence of a family history that meets the Amsterdam II criteria) for which a mutation has not been identified. Recently, the identification of a novel genetic mechanism for the inactivation of the MSH2 gene has been described whereby deletions of the 3 0 end of the EPCAM gene creates an EPCAM/MSH2 fusion transcript resulting in methylation of the MSH2 promoter and transcriptional silencing [5] , however these do not account for all the families in which CRC cases have a tumour displaying loss of staining for the MSH2 and MSH6 heterodimer proteins but have no identifiable mutation.
MMR gene mutation detection by both research and clinical laboratories has focused on routine sequence analysis of the transcribed regions such that only short stretches of intronic sequence flanking the exons are screened. This practice is reflected by an analysis of the Leiden Open Variation Database (www.lovd.nl) where 90% of the variants identified within introns of the MSH2 gene (n = 761) occur within 20 bp of the exon, and the majority of those seen deeper within the intron have come from only two studies which have measured non-deleterious tagging SNPs across the genomic region [6, 7] .
In this study we describe a family with Lynch syndrome caused by a novel MSH2 mutation situated deep within intron 1 (4,521 bp downstream from exon 1 and 478 bp upstream of exon 2), demonstrating the benefit of a more extensive sequencing approach for such families.
Methods and results
Family X ( Fig. 1 ; Table 1 ) was recruited through the Australasian Colorectal Cancer Family Study (ACCFS) [8] , under the study recruitment guidelines of a family meeting the Amsterdam II criteria [2] . Colorectal tumour material was available for MMR IHC staining and MSI testing [4] for individuals 1, 9 and 12. All three demonstrated microsatellite instability and/or tumour-specific loss of MSH2 and MSH6 proteins (Table 1) . Sanger sequencing and MLPA testing for mutations [9] in individual 9 identified no pathogenic mutations or variants of uncertain clinical significance within MSH2 or the EPCAM gene. Testing for mutations in MSH6, the heterodimeric partner of MSH2, also identified no pathogenic or unclassified variants.
A panel of seven previously described [10] microsatellite markers spanning 4.2 Mb across chromosome 2p, inclusive of the MSH2, MSH6 and EPCAM genes, was used to identify a disease-segregating haplotype and hence establish that a genetic connection existed between the tumour IHC MMR deficiency and affected members of the family. Affected individuals 1 and 9, who are first cousins once removed, demonstrated a shared haplotype across the MSH2 locus ( Fig. 1 ) and thus provided evidence against possible somatic inactivation of MMR. This conserved haplotype was also seen in individual 10 who is currently unaffected, but it has not previously been observed amongst a set of 118 healthy Caucasian controls [10] .
In the absence of a coding mutation or gene re-arrangement, we hypothesised that the shared haplotype in Family X harboured a variant causing aberrant regulation or splicing of the MSH2 gene. To address this hypothesis, immortalised lymphoblastoid cell lines were generated Table 1 following the principles of Sugden and Mark [11] . Cell lines were cultured in the presence of 100 lg/ml of cycloheximide to eliminate nonsense mediated decay, and RNA was subsequently extracted using TRIzol Ò reagent (Invitrogen). To detect aberrant splicing, complementary DNA (cDNA) was generated, using the ImProm-II TM Reverse Transcription System (Promega), for individuals 9 and 10 of Family X and from three blood donor controls. This cDNA was then used to amplify the MSH2 gene in four overlapping fragments (Supplementary Table 1 ) that were resolved on a 2% agarose gel.
An aberrant band approximately 100 bp larger than the wild type band was seen in individuals 9 and 10 for the amplicon spanning exons 1 through 4 (Fig. 2a) . It can be seen from lanes 1 and 3, which distinguish between cycloheximide treated and untreated cell lines, that nonsense mediated decay is involved in breaking down some of the aberrant splice form, however a significant level of transcript still remains in the untreated cells (lane 3). This aberrant banding was not observed in unrelated controls, and no other patient specific aberrations could be seen in the remaining amplicons (Supplementary Figure 1) . To characterise the nucleotide sequence of the larger aberrant product, the band was excised and DNA extracted from the agarose gel, using Qiagen's QIAquick gel extraction kit. Sanger sequencing of the DNA fragment revealed an insertion of 75 nucleotides between the end of exon 1 and the beginning of exon 2 (Fig. 2b) , the sequence of which mapped to deep within intron 1 of MSH2 (c.212-553_c.212-479). Primers were generated (Supplementary Table 1 ) to amplify across the identified inserted region of intron 1. Subsequent germline sequencing revealed a T [ G nucleotide change at intronic position c.212-478 for individuals 1, 2, 9 and 10 but not for individual 11, concordant with the segregating haplotype (Fig. 1) . This T [ G transversion results in the formation of a canonical splice donor site at the 3 0 end of the inserted sequence (NNSPLICE 0.9, score = 1), which together with an existing predicted cryptic acceptor site at the 5 0 end (NNSPLICE 0.9, score = 0.8) accounted for the observed insertion and aberrant transcript (Fig. 3) . The inserted sequence is in-frame with the wild type transcript, however it contains a stop codon at the 3 0 end and is predicted to result in a truncated protein of just 94 amino acids. The variant is not recorded in dbSNP nor was it seen amongst a set of 100 healthy blood donor controls.
Conclusion
This study has identified a novel mutation in the MSH2 locus and provides evidence for a mechanism of disease causation for rare intronic variants far removed from the traditional splice sites. This type of mutation mechanism has been previously reported for cystic fibrosis [12] , but has not been previously described in Lynch syndrome. We have not excluded the possibility that the mutation identified here is family specific, however, additional intronic mutations located outside of the current screening regions may be present in families without an identified mutation. An analysis of the intronic sequences within MSH2 revealed additional putative splice donor (n = 163) or splice acceptor (n = 284) sites (NNSPLICE 0.9, score C 0.75) which could potentially be involved in cryptic splicing given an upstream or downstream mutation which creates a complementary splice acceptor or splice donor site, respectively.
These current findings highlight the success of additional molecular studies in families with suspected Lynch syndrome and demonstrate the potential benefit of utilising more extensive sequence analysis methods to identify causative mutations in suspected Lynch syndrome families where routine methods have failed to find a causative mutation. 
